PDGFRB and AL amyloidosis: Finally, our findings also suggest that combination of PDGFR inhibition and sclerostin neutralization could represent a powerful approach to rapidly increase bone mass and strength in patients with osteolytic lesions provoked by multiple myeloma or bone metastases involving excessive PDGFR activity (24, 25).